Is there a role for Gallium-67 SPECT in distinguishing progression and pseudoprogresion in oncologic patients receiving immunotherapy?
Open Access
- 1 January 2021
- journal article
- case report
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 28, 100441
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract CancerCancers, 2021
- Turning Cold into Hot: Firing up the Tumor MicroenvironmentTrends in Cancer, 2020
- Pseudoprogression and Hyperprogression as New Forms of Response to ImmunotherapyBioDrugs, 2020
- Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysisJournal for ImmunoTherapy of Cancer, 2020
- Directing Traffic: How to Effectively Drive T Cells into TumorsCancer Discovery, 2020
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapiesNature Reviews Drug Discovery, 2019
- Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trialThe Lancet Oncology, 2018
- Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancerWorld Journal of Urology, 2018
- Mechanisms regulating T-cell infiltration and activity in solid tumorsAnnals of Oncology, 2017
- irRECIST and iRECIST: the devil is in the detailsAnnals of Oncology, 2017